Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.69 |
| ▸ | POLB | P06746 | 2/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | THRB | P10828 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | TGM2 | P21980 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 7/20 | 0.50 |
| ▸ | CA1 | P00915 | 6/20 | 0.50 |
| ▸ | CA9 | Q16790 | 6/20 | 0.50 |
| ▸ | CA12 | O43570 | 5/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.48 |
| ▸ | FYN | P06241 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15333772 | 1.00 | LMNA (0.69) | LMNAKMT2APOLBALDH1A1CYP3A4 | |
| SCHEMBL12847513 | 1.00 | LMNA (0.69) | LMNAKMT2APOLBALDH1A1CYP3A4 | |
| SCHEMBL404573 | 1.00 | LMNA (0.69) | LMNAKMT2APOLBALDH1A1CYP3A4 | |
| SCHEMBL16217766 | 1.00 | LMNA (0.69) | LMNAKMT2APOLBALDH1A1CYP3A4 | |
| SCHEMBL15494655 | 1.00 | LMNA (0.69) | LMNAKMT2APOLBALDH1A1CYP3A4 | |
| SCHEMBL24771437 | 1.00 | LMNA (0.69) | LMNAKMT2APOLBALDH1A1CYP3A4 | |
| SCHEMBL7147808 | 1.00 | LMNA (0.69) | LMNAKMT2APOLBALDH1A1CYP3A4 | |
| SCHEMBL20516514 | 1.00 | LMNA (0.69) | LMNAKMT2APOLBALDH1A1CYP3A4 | |
| SCHEMBL22927890 | 1.00 | LMNA (0.69) | LMNAKMT2APOLBALDH1A1CYP3A4 | |
| SCHEMBL3631711 | 1.00 | LMNA (0.69) | LMNAKMT2APOLBALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 140 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12605451-B2 | Targeted plasma protein degradation | NOVARTIS AG (CH) | 2026-04-21 | — | — | US | disclosed |
| US-20260083851-A1 | POTENT ASGPR-BINDING HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2026-03-26 | — | — | US | disclosed |
| EP-3247328-B1 | METHODS, COMPOSITIONS, AND SYSTEMS FOR DELIVERING THERAPEUTIC AND DIAGNOSTIC AGENTS INTO CELLS | GENEVANT SCIENCES GMBH (CH) | 2026-01-07 | — | — | EP | disclosed |
| US-12486503-B2 | Short interfering nucleic acid (siNA) compositions | SIRNA THERAPEUTICS, INC. (US) | 2025-12-02 | — | — | US | disclosed |
| US-20250276000-A1 | METHODS, COMPOSITIONS, AND SYSTEMS FOR DELIVERING THERAPEUTIC AND DIAGNOSTIC AGENTS INTO CELLS | GENEVANT SCIENCES GMBH (CH) | 2025-09-04 | — | — | US | disclosed |
| US-20250186599-A1 | BLOCK COPOLYMERS | GENEVANT SCIENCES GMBH (CH) | 2025-06-12 | — | — | US | disclosed |
| CN-114621951-B | Nucleic acid for targeting hepatitis B virus and application thereof | 施能康生物科技有限公司 | 2025-05-30 | — | — | CN | disclosed |
| US-12304925-B2 | Tetragalnac and peptide containing conjugates and methods for delivery of oligonucleotides | SIRNA THERAPEUTICS, INC. (US) | 2025-05-20 | — | — | US | disclosed |
| WO-2024240101-A9 | GALNAC COMPOUND, CONJUGATE, COMPOSITION, AND USE THEREOF | 北京炫景瑞医药科技有限公司 | 2025-03-06 | — | — | WO | disclosed |
| WO-2024240101-A1 | GALNAC COMPOUND, CONJUGATE, COMPOSITION, AND USE THEREOF | 北京炫景瑞医药科技有限公司 | 2024-11-28 | — | — | WO | disclosed |
| EP-2844261-A2 | SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS | Sirna Therapeutics, Inc. (US) | 2015-03-11 | — | — | EP | disclosed |
| WO-2013166121-A1 | NOVEL TETRAGALNAC CONTAINING CONJUGATES AND METHODS FOR DELIVERY OF OLIGONUCLEOTIDES | MERCK SHARP & DOHME CORP. (US) | 2013-11-07 | — | — | WO | disclosed |
| WO-2013165816-A2 | SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS | MERCK SHARP & DOHME CORP. (US) | 2013-11-07 | — | — | WO | disclosed |
| WO-2013166121-A1 | NOVEL TETRAGALNAC CONTAINING CONJUGATES AND METHODS FOR DELIVERY OF OLIGONUCLEOTIDES | MERCK SHARP & DOHME CORP. (US) | 2013-11-07 | — | — | WO | disclosed |
| WO-2013166155-A1 | NOVEL TETRAGALNAC AND PEPTIDE CONTAINING CONJUGATES AND METHODS FOR DELIVERY OF OLIGONUCLEOTIDES | MERCK SHARP & DOHME CORP. (US) | 2013-11-07 | — | — | WO | disclosed |
| WO-2013165816-A2 | SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS | MERCK SHARP & DOHME CORP. (US) | 2013-11-07 | — | — | WO | disclosed |
| WO-2013166155-A1 | NOVEL TETRAGALNAC AND PEPTIDE CONTAINING CONJUGATES AND METHODS FOR DELIVERY OF OLIGONUCLEOTIDES | MERCK SHARP & DOHME CORP. (US) | 2013-11-07 | — | — | WO | disclosed |
| US-4362720-A | Synthesis of 2-amino-2-deoxyglycoses and 2-amino-2-deoxyglycosides from glycals | CHEMBIOMED LTD. (CA) | 1982-12-07 | — | — | US | disclosed |
| US-4308376-A | Synthesis of 2-amino-2-deoxyglycoses and 2-amino-2-deoxyglycosides from glycals | CHEMBIOMED LTD. (CA) | 1981-12-29 | — | — | US | disclosed |
| US-4195174-A | Synthesis of 2-amino-2-deoxyglycoses and 2-amino-2-deoxyglycosides from glycals | CHEMBIOMED LTD. (CA) | 1980-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250186599-A1 | BLOCK COPOLYMERS | CHMP4B, CD47, EEA1 | LMNA 1251/4885KMT2A 4428/4885POLB 320/4885 |
| US-20250276000-A1 | METHODS, COMPOSITIONS, AND SYSTEMS FOR DELIVERING THERAPEUTIC AND DIAGNOSTIC AGENTS INTO CELLS | CD63, LIPA, NPC1L1 | LMNA 146/4885KMT2A 4574/4885POLB 2396/4885 |
| US-20260083851-A1 | POTENT ASGPR-BINDING HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS | ASGR1, FCGR2A, FCGR3B | LMNA 3350/4885KMT2A 4453/4885POLB 4359/4885 |
| US-12605451-B2 | Targeted plasma protein degradation | M6PR, ASGR1, IGF2R | LMNA 1051/4885KMT2A 2504/4885POLB 4286/4885 |
| US-12304925-B2 | Tetragalnac and peptide containing conjugates and methods for delivery of oligonucleotides | GALNT3, B3GAT3, CSGALNACT1 | LMNA 1364/4885KMT2A 4359/4885POLB 1998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.